drug · protein
povetacicept
Phase 3updated 5mo agoby $VERX Vertex, Inc.🔗 ChEMBL
Phase 3community read0 votes
Protein drug with a maximum clinical stage of Phase 3 (across all indications), with 4 investigational indications.
all catalysts(0)
nothing on the calendar yet
Trials studying povetacicept
- phase3Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
- phase3A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy
- phase2A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
- phase3Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
- phase2An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
- phase1A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Presentations
- phase2An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias
News(7)
- Vertex opens up larger kidney disease opportunity with mid-stage readoutWhile Vertex is laser-focused on an upcoming FDA decision for povetacicept in immunoglobulin A nephropathy, the APOL1 inhibitor inaxaplin has demonstrated potential “best-in-class” data in a differ…biospace · 7d ago
- Frazier adds $1.1B+ to small and mid-sized biotech fundFrazier’s life science fund has already benefited several successful biotechs, including Verona Pharma, which was acquired by Merck for $10 billion, and Carmot Therapeutics, which Roche bought for…biospace · 18d ago
- Deerfield-backed Boulevard Bio embarks on ‘beautiful path to a cure’ with trio of immunology drugsBoulevard Bio has strolled out of stealth with $65 million in funding from Deerfield Management and three autoimmune disease candidates.fiercebiotech · 1mo ago
- Vertex unfazed by competitive IgAN space as FDA verdict loomsPositive two-year follow-up data for Otsuka Pharmaceuticals’ IgA nephropathy drug Voyxact could support the FDA’s ongoing review of Vertex Pharmaceuticals’ povetacicept, CEO Reshma Kewalramani said…biospace · 1mo ago
- Vertex’s IgA nephropathy drug derisked after Novartis, Vera approvalsThe FDA is currently reviewing Vertex Pharmaceuticals’ povetacicept, with a target action date of Nov. 30. If approved, the drug could benefit from campaigns from Novartis and Vera Therapeutics for…biospace · 2mo ago
- 10 clinical trials to watch in the second half of 2026The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to the momentum.biopharma_dive · 3mo ago
- Vertex earnings get muted investor responseWhile overall revenue fell just shy of Wall Street forecasts, sales of the gene editing medicine Casgevy and pain drug Journavx missed analyst estimates by double-digit percentages.biopharma_dive · 4mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that